| Literature DB >> 36186099 |
Mohammad Abazari1, Mahdi Yousefi1, Vafa Baradaran Rahimi2, Hamideh Vahid1, Azadeh Saki3, Arash Gholoobi2.
Abstract
Objectives: Routine therapies cannot control refractory stable angina, leading to a high economic burden and an impaired quality of life. Persian medicine incorporates exceptional attention to lifestyle and nutrition to prevent and treat various diseases. Previous studies have reported the analgesic and anti-inflammatory effects of wet cupping. The present study aims to determine the effects of nutrition and cupping on refractory stable angina patients.Entities:
Keywords: nutrition; persian medicine; refractory stable angina; wet cupping
Year: 2022 PMID: 36186099 PMCID: PMC9510135 DOI: 10.3831/KPI.2022.25.3.224
Source DB: PubMed Journal: J Pharmacopuncture ISSN: 2093-6966
Diet plan
| Meal | Foods |
|---|---|
| Breakfast | - Mung beans or beans with two loaves of bread |
| Lunch | - Barley soup containing barley, coriander, mung bean, lettuce and zucchini |
| Dinner | - Pumpkin feed and pomegranate juice |
| Snack | - Snacks: dried berries, figs |
| Abstinence | - Overeating or starvation |
Figure 1The location and manner of cupping.
Figure 2The study flowchart.
Participants’ demographic information
| Mean ± SD or N (%) | Group | p-value | |||
|---|---|---|---|---|---|
|
| |||||
| A | B | C | D | ||
| Age (years) | 56.60 ± 9.5 | 49.40 ± 6.99 | 52.3 ± 7.24 | 54.40 ± 9.6 | 0.28 |
| BMI (kg/m2) | 25.60 ± 3.55 | 24.40 ± 3.85 | 26.13 ± 2.63 | 25.52 ± 2.49 | 0.68 |
| Duration of disease | 0.54 | ||||
| < 5 years | 3 (30.0) | 4 (40.0) | 4 (40.0) | 1 (10.0) | |
| 6-10 years | 2 (20.0) | 3 (30.0) | 3 (30.0) | 6 (60.0) | |
| > 10 years | 5 (50.0) | 3 (30.0) | 3 (30.0) | 3 (30.0) | |
| Angioplasty | 0.24 | ||||
| 1-5 | 8 (80) | 5 (50) | 4 (40) | 9 (90) | |
| 6-10 | 1 (10) | 2 (20) | 3 (30) | 0 (00) | |
| > 10 | 1 (10) | 3 (30) | 3 (30) | 1 (10) | |
| CABG | 0.88 | ||||
| Yes | 3 (30.0) | 3 (30.0) | 5 (50.0) | 4 (40.0) | |
| No | 7 (70.0) | 7 (70.0) | 5 (50.0) | 6 (60.0) | |
The exercise test results before (day 0) and after (day 30) treatment
| Exercise test | Group | p-valuea | |||
|---|---|---|---|---|---|
|
| |||||
| A | B | C | D | ||
| Baseline | 11.0 ± 4.54 | 8.40 ± 4.99 | 11.80 ± 4.98 | 14.30 ± 6.0 | 0.1 |
| End | 17.60 ± 2.63 | 16.66 ± 4.53 | 20.30 ± 2.83 | 12.80 ± 6.24 | 0.004 |
| Discord | ↑6.60 ± 4.24 | ↑8.20 ± 4.69 | ↑8.50 ± 4.69 | ↓1.5 ± 5.02 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.38 | - |
↑: Increment, ↓: Decrement; ***p < 0.001 comparing the mentioned group and its control group, aresults of ANOVA test between four groups, bresults of paired t-test comparison before and after the treatment.
The SBP and DBP results before (day 0) and after (day 30) treatment
| mmHg; Mean ± SD | Group | p-valuea | |||
|---|---|---|---|---|---|
|
| |||||
| A | B | C | D | ||
| SBP | |||||
| Baseline | 129.6 ± 18.055 | 130.9 ± 14.95 | 133.20 ± 15.06 | 119.40 ± 15.54 | 0.24 |
| End | 123.0 ± 16.85 | 123.0 ± 12.81 | 116.80 ± 15.50 | 126.0 ± 14.68 | 0.56 |
| Discord | ↓9.30 ± 12.69 | ↓14.10 ± 14.98 | ↓9.90 ± 7.39 | ↑6.60 ± 8.57 | 0.002 |
| p-valueb | 0.06 | 0.01 | 0.002 | 0.04 | - |
| DBP | |||||
| Baseline | 79.70 ± 11.80 | 84.30 ± 10.40 | 79.30 ± 7.0 | 78.10 ± 10.24 | 0.54 |
| End | 71.60 ± 8.03 | 72.20 ± 8.96 | 74.90 ± 8.69 | 81.50 ± 6.95 | 0.04 |
| Discord | ↓8.10 ± 6.78 | ↓12.10 ± 7.50 | ↓4.40 ± 7.50 | ↑3.40 ± 7.69 | 0.001 |
| p-valueb | 0.004 | 0.001 | 0.1 | 0.19 | - |
↑: Increment, ↓: Decrement; *p < 0.05, **p < 0.01, and ***p < 0.001 comparing the mentioned group and its control group, aresults of ANOVA test between four groups, bresults of paired-t-test before and after the treatment.
The SAQ results before (day 0) and after (day 30) treatment
| Mean ± SD | Group | p-valuea | |||
|---|---|---|---|---|---|
|
| |||||
| A | B | C | D | ||
| Physical limitation | |||||
| Baseline | 20.30 ± 2.49 | 20.0 ± 6.14 | 20.80 ± 5.24 | 25.40 ± 3.24 | 0.04 |
| End | 35.20 ± 4.96 | 36.80 ± 2.48 | 37.0 ± 4.61 | 23.70 ± 5.01 | < 0.001 |
| Discord | ↑14.90 ± 6.75 | ↑16.80 ± 8.11 | ↑16.20 ± 5.97 | 1.7 ± 4.62 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.28 | - |
| Angina stability | |||||
| Baseline | 2.70 ± 1.33 | 2.0 ± 1.15 | 2.30 ± 0.94 | 4.0 ± 0.66 | 0.001 |
| End | 5.40 ± 0.96 | 5.40 ± 0.69 | 5.30 ± 0.82 | 4.30 ± 1.82 | 0.11 |
| Discord | ↑2.70 ± 0.95 | ↑3.40 ± 0.96 | ↑3.0 ± 0.97 | ↑0.30 ± 2.32 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.68 | - |
| Angina frequency | |||||
| Baseline | 5.0 ± 1.88 | 4.30 ± 2.54 | 4.40 ±2.06 | 8.0 ± 2.44 | 0.002 |
| End | 10.70 ± 1.25 | 10.1 ± 1.52 | 10.0 ± 0.66 | 8.4 ± 2.59 | 0.02 |
| Discord | ↑5.70 ± 1.70 | ↑5.8 ± 0.96 | ↑5.60 ± 2.12 | ↑0.40 ± 3.80 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.74 | - |
| Treatment satisfaction | |||||
| Baseline | 8.40 ± 1.98 | 7.10 ± 2.55 | 7.30 ± 2.31 | 8.70 ± 2.0 | 0.30 |
| End | 18.70 ± 2.98 | 18.80 ± 1.8 | 7.40 ± 1.83 | 12.20 ± 4.10 | < 0.001 |
| Discord | ↑10.30 ± 3.50 | ↑11.70 ± 3.71 | ↑4.40 ± 1.77 | ↑3.50 ± 5.20 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.07 | - |
| Disease perception | |||||
| Baseline | 2.90 ± 0.87 | 2.30 ± 0.65 | 3.0 ± 1.94 | 2.9 ± 1.3 | 0.63 |
| End | 7.90 ± 1.10 | 6.80 ± 1.3 | 7.40 ± 1.83 | 3.9 ± 2.51 | < 0.001 |
| Discord | ↑5.0 ± 1.56 | ↑4.50 ± 0.97 | ↑4.40 ± 1.77 | ↑1.0 ± 2.54 | < 0.001 |
| p-valueb | 0.001 | 0.001 | 0.001 | 0.001 | - |
↑: Increment, *p < 0.05 and ***p < 0.001 comparing the mentioned group and its control group, aresults of ANOVA test between four groups, bresults of paired-t-test before and after the treatment.
The VAS results before (day 0) and after the first, second, and third months of treatment
| Mean ± SD | Group | p-valuea | |||
|---|---|---|---|---|---|
|
| |||||
| A | B | C | D | ||
| Baseline | 8.6 ± 0.96 | 8.1 ± 1.28 | 8.0 ± 0.94 | 5.3 ± 2.62 | < 0.001 |
| First | 3.4 ± 1.64 | 3.7 ± 2.66 | 3.3 ± 2.71 | 6.5 ± 1.77 | < 0.001 |
| Second | 1.9 ± 1.1 | 2.1 ± 1.65 | 1.9 ± 1.37 | 7.0 ± 1.63 | < 0.001 |
| Third | 1.3 ± 2.75 | 1.0 ± 1.84 | 0.4 ± 0.52 | 7.0 ± 1.88 | < 0.001 |
| Discord | ↓7.3 ± 2.8 | ↓7.1 ± 2.28 | ↓7.6 ± 0.84 | ↑1.7 ± 3.43 | < 0.001 |
| p-valueb | < 0.001 | < 0.001 | < 0.001 | 0.12 | - |
↑: Increment, ↓: Decrement; ***p < 0.001 comparing the mentioned group and its control group, aresults of ANOVA test between four groups, brepeated measurements ANOVA results in each group before and after the first, second, and third months of treatment.